BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7751894)

  • 1. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?
    Jansson T; Westlin JE; Ahlström H; Lilja A; Långström B; Bergh J
    J Clin Oncol; 1995 Jun; 13(6):1470-7. PubMed ID: 7751894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
    Wahl RL; Zasadny K; Helvie M; Hutchins GD; Weber B; Cody R
    J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
    Bassa P; Kim EE; Inoue T; Wong FC; Korkmaz M; Yang DJ; Wong WH; Hicks KW; Buzdar AU; Podoloff DA
    J Nucl Med; 1996 Jun; 37(6):931-8. PubMed ID: 8683314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
    Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography in the diagnosis and staging of urinary bladder cancer.
    Ahlström H; Malmström PU; Letocha H; Andersson J; Långström B; Nilsson S
    Acta Radiol; 1996 Mar; 37(2):180-5. PubMed ID: 8600958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
    Schelling M; Avril N; Nährig J; Kuhn W; Römer W; Sattler D; Werner M; Dose J; Jänicke F; Graeff H; Schwaiger M
    J Clin Oncol; 2000 Apr; 18(8):1689-95. PubMed ID: 10764429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury.
    Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K
    Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer.
    Lindholm P; Leskinen-Kallio S; Minn H; Bergman J; Haaparanta M; Lehikoinen P; Någren K; Ruotsalainen U; Teräs M; Joensuu H
    J Nucl Med; 1993 Oct; 34(10):1711-6. PubMed ID: 8410288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
    Gennari A; Donati S; Salvadori B; Giorgetti A; Salvadori PA; Sorace O; Puccini G; Pisani P; Poli M; Dani D; Landucci E; Mariani G; Conte PF
    Clin Breast Cancer; 2000 Jul; 1(2):156-61; discussion 162-3. PubMed ID: 11899654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
    van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
    J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PET scan in general practice for diagnosis of breast carcinoma].
    Ruhlmann J; Oehr P; Bender H; Kozak B; Willkomm P; Schräder M; Biersack HJ
    Acta Med Austriaca; 1997; 24(2):63-7. PubMed ID: 9273808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
    Smith IC; Welch AE; Hutcheon AW; Miller ID; Payne S; Chilcott F; Waikar S; Whitaker T; Ah-See AK; Eremin O; Heys SD; Gilbert FJ; Sharp PF
    J Clin Oncol; 2000 Apr; 18(8):1676-88. PubMed ID: 10764428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma.
    Dethy S; Goldman S; Blecic S; Luxen A; Levivier M; Hildebrand J
    J Nucl Med; 1994 Jul; 35(7):1162-6. PubMed ID: 8014676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers.
    Bruce DM; Evans NT; Heys SD; Needham G; BenYounes H; Mikecz P; Smith FW; Sharp F; Eremin O
    Eur J Surg Oncol; 1995 Jun; 21(3):280-3. PubMed ID: 7781797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
    Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
    J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.